Authors:
Krug, LM
Ng, KK
Kris, MG
Miller, VA
Tong, W
Heelan, RT
Leon, L
Leung, D
Kelly, J
Sirotnak, FM
Citation: Lm. Krug et al., Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate (vol 6, pg 3493, 2000), CLIN CANC R, 7(4), 2001, pp. 1102-1102
Authors:
Krug, LM
Ng, KK
Kris, MG
Miller, VA
Tong, W
Heelan, RT
Leon, L
Leung, D
Kelly, J
Sirotnak, FM
Citation: Lm. Krug et al., Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate, CLIN CANC R, 6(9), 2000, pp. 3493-3498
Authors:
Sirotnak, FM
Wendel, HG
Bornmann, WGB
Tong, WP
Miller, VA
Scher, HI
Kris, MG
Citation: Fm. Sirotnak et al., Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo, CLIN CANC R, 6(9), 2000, pp. 3705-3712
Authors:
Soignet, SL
Miller, VA
Pfister, DG
Bienvenu, BJ
Ho, R
Parker, BA
Amyotte, SA
Cato, A
Warrell, RP
Citation: Sl. Soignet et al., Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550), CLIN CANC R, 6(5), 2000, pp. 1731-1735
Authors:
Sirotnak, FM
Zakowski, MF
Miller, VA
Scher, HI
Kris, MG
Citation: Fm. Sirotnak et al., Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase, CLIN CANC R, 6(12), 2000, pp. 4885-4892
Authors:
Miller, VA
Krug, LM
Ng, KK
Pizzo, B
Perez, W
Heelan, RT
Kris, MG
Citation: Va. Miller et al., Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer, J CL ONCOL, 18(6), 2000, pp. 1346-1350
Citation: Va. Miller et Mg. Kris, Docetaxel (Taxotere) as a single agent and in combination chemotherapy forthe treatment of patients with advanced non-small cell lung cancer, SEMIN ONCOL, 27(2), 2000, pp. 3-10
Authors:
Miller, VA
Ng, KK
Krug, LM
Perez, W
Pizzo, B
Heelen, RT
Kris, MG
Citation: Va. Miller et al., Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma, CANCER, 88(5), 2000, pp. 1045-1050
Authors:
Dickler, MN
Ragupathi, G
Liu, NX
Musselli, C
Martino, DJ
Miller, VA
Kris, MG
Brezicka, FT
Livingston, PO
Grant, SC
Citation: Mn. Dickler et al., Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer, CLIN CANC R, 5(10), 1999, pp. 2773-2779
Authors:
Rigas, JR
Kris, MG
Miller, VA
Pisters, KMW
Heelan, RT
Grant, SC
Fennelly, DW
Chou, TC
Sirotnak, FM
Citation: Jr. Rigas et al., Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors, ANN ONCOL, 10(5), 1999, pp. 601-603
Citation: Lm. Krug et Va. Miller, Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer, SEMIN ONCOL, 26(5), 1999, pp. 24-26
Authors:
Krug, LM
Grant, SC
Miller, VA
Ng, KK
Kris, MG
Citation: Lm. Krug et al., Strategies to eradicate minimal residual disease in small cell lung cancer: High-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination, SEMIN ONCOL, 26(5), 1999, pp. 55-61
Authors:
Ng, KK
Kris, MG
Ginsberg, RJ
Heelan, RT
Pisters, KMW
Miller, VA
Grant, SG
Bains, M
Rusch, V
Rosenzweig, KE
Martini, N
Citation: Kk. Ng et al., Induction chemotherapy employing dose-intense cisplatin with mitomycin andvinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma, CANCER, 86(7), 1999, pp. 1189-1197